Globe Newswire04.10.19
Soliton Inc., a medical technology company that has developed a new acoustic shockwave device, announced that the National Intellectual Property Administration (Chinese Patent Office) has issued a notice of grant for Chinese Patent Application No. 201280041817.2, based on International Application No.PCT/IS2012/046674; Entitled “Apparatus for Generating Therapeutic Shockwaves And Applications of Same,” by Christopher C. Capelli.
Dr. Chris Capelli, CEO of Soliton, said, “The granting of this patent is an important milestone for Soliton. With the issuance of this patent in the People’s Republic of China (PRC) for our Rapid Acoustic Pulse (RAP) technology and with our pending United States patents, we are well positioned to develop two of the major consumer markets in the world. We have a strong portfolio that now numbers 38 issued and pending patents that we believe provides Soliton a meaningful competitive advantage in removing unwanted tattoos in about one-third of the time of traditional procedures, with less pain and discomfort, and at a lower overall cost.”
Soliton has discovered other capabilities of the RAP technology during preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as potentially reducing the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth. Importantly, this potential indication could position Soliton RAP as a stand-alone device, without the need for lasers or other procedures.
Dr. Capelli concluded, “If our ongoing clinical trials prove to be effective in cellulite and fat removal, we will dramatically expand our addressable markets. We are excited with the opportunities ahead in the coming years.”
Soliton Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The company’s first planned commercial product will use rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The company is based in Houston, Texas, and is actively engaged in bringing this device to the market. The company expects to receive clearance to market the device in mid 2019. This initial filing is limited to the company’s device used in conjunction with the 1064 nm Q-switched laser to enable effective multiple pass laser treatments in a single office session to accelerate removal of black tattoos on the arms, legs and torso in Fitzpatrick Skin Type I-III individuals. While the company believes its’ technology has many potential applications, the company has initially focused on the removal of tattoos, where both animal and human studies have shown promising results. The current standard of care for tattoo removal is to use a Q-switched (pulsed) laser to ablate the tattoo ink particles into pieces small enough for the body’s natural processes to remove them.
Unfortunately, this current method is highly inefficient, requiring up to 10 or more office visits to achieve acceptable results. A clinical trial has demonstrated that using the company’s RAP device, in conjunction with a Q-switched laser, has the potential to produce similar results in just two to three office visits versus the industry average of 10 or more with a stand-alone laser. The company believes this “Soliton” method can not only dramatically accelerate tattoo removal, but also has the potential to lower removal cost for patients, while increasing profitability to practitioners, and to reduce the potential for unwanted side effects from current laser removal methods.
Dr. Chris Capelli, CEO of Soliton, said, “The granting of this patent is an important milestone for Soliton. With the issuance of this patent in the People’s Republic of China (PRC) for our Rapid Acoustic Pulse (RAP) technology and with our pending United States patents, we are well positioned to develop two of the major consumer markets in the world. We have a strong portfolio that now numbers 38 issued and pending patents that we believe provides Soliton a meaningful competitive advantage in removing unwanted tattoos in about one-third of the time of traditional procedures, with less pain and discomfort, and at a lower overall cost.”
Soliton has discovered other capabilities of the RAP technology during preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as potentially reducing the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth. Importantly, this potential indication could position Soliton RAP as a stand-alone device, without the need for lasers or other procedures.
Dr. Capelli concluded, “If our ongoing clinical trials prove to be effective in cellulite and fat removal, we will dramatically expand our addressable markets. We are excited with the opportunities ahead in the coming years.”
Soliton Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The company’s first planned commercial product will use rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The company is based in Houston, Texas, and is actively engaged in bringing this device to the market. The company expects to receive clearance to market the device in mid 2019. This initial filing is limited to the company’s device used in conjunction with the 1064 nm Q-switched laser to enable effective multiple pass laser treatments in a single office session to accelerate removal of black tattoos on the arms, legs and torso in Fitzpatrick Skin Type I-III individuals. While the company believes its’ technology has many potential applications, the company has initially focused on the removal of tattoos, where both animal and human studies have shown promising results. The current standard of care for tattoo removal is to use a Q-switched (pulsed) laser to ablate the tattoo ink particles into pieces small enough for the body’s natural processes to remove them.
Unfortunately, this current method is highly inefficient, requiring up to 10 or more office visits to achieve acceptable results. A clinical trial has demonstrated that using the company’s RAP device, in conjunction with a Q-switched laser, has the potential to produce similar results in just two to three office visits versus the industry average of 10 or more with a stand-alone laser. The company believes this “Soliton” method can not only dramatically accelerate tattoo removal, but also has the potential to lower removal cost for patients, while increasing profitability to practitioners, and to reduce the potential for unwanted side effects from current laser removal methods.
